Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa
October 08 2020 - 4:30PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today
that Adam Muzikant, Ph.D., Senior Vice President, Business
Development, will present at the annual 2020 Cell & Gene
Virtual Meeting on the Mesa. Dr. Muzikant will provide a review of
FX201, an investigational, intra-articular, IL-1Ra gene therapy
product candidate in clinical development for the treatment of
osteoarthritis (OA).
The Company is conducting an open-label, Phase 1 dose-escalation
trial evaluating the safety and tolerability of FX201 in patients
with knee OA. The trial is intended to test low, mid and high doses
of FX201 in cohorts of five to eight patients. Following the
completion of the low-dose cohort and data review by an independent
Drug Monitoring Committee, the trial has advanced to enrolling the
mid-dose cohort. Data from the study are anticipated in 2021.
Organized by the Alliance for Regenerative Medicine, the
2020 Cell & Gene Meeting on the Mesa will be delivered in a
virtual format over the course of five days beginning on October
12. The conference will feature more than 120 presentations by
leading public and private companies highlighting the technical and
clinical achievements in the areas of cell therapy, gene therapy,
gene editing, tissue engineering and broader regenerative medicine
technologies.
About FX201FX201
(humantakinogene hadenovec) is a novel, clinical-stage,
intra-articular gene therapy product candidate which utilizes a
helper-dependent adenovirus (HDAd) vector based on human serotype 5
(Ad5) that is designed to transfer a gene to cells in the joint to
produce an anti-inflammatory protein, interleukin-1 receptor
antagonist (IL-1Ra), under the control of an inflammation-sensitive
promoter. Inflammation is a known cause of pain, and chronic
inflammation is thought to play a major role in the progression of
OA. By persistently suppressing inflammation, Flexion believes
FX201 holds the potential to provide long-term pain relief and
functional improvement, and to modify disease progression.
About Flexion TherapeuticsFlexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with OA, the most common form of arthritis.
The company's core values are focus, ingenuity, tenacity,
transparency and fun. Visit flexiontherapeutics.com.
Forward-Looking Statements This release
contains forward-looking statements that are based on the current
expectations and beliefs of Flexion. Statements in this press
release regarding matters that are not historical facts, including,
but not limited to, statements relating to the future of Flexion;
timing and plans with respect to the Phase 1 clinical trial of
FX201; and the potential therapeutic and other benefits of FX201,
are forward looking statements. These forward-looking statements
are based on management’s expectations and assumptions as of the
date of this press release and are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, without limitation, the fact
that the impacts and expected duration of the COVID-19 pandemic are
uncertain and rapidly changing; the risk that we may not be able to
maintain and enforce our intellectual property, including
intellectual property related to FX201; risks related to clinical
trials, including potential delays, safety issues or negative
results; and other risks and uncertainties described in our filings
with the Securities and Exchange Commission (SEC), including under
the heading “Risk Factors” in our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2020 filed with the SEC on August 5,
2020 and subsequent filings with the SEC. The forward-looking
statements in this press release speak only as of the date of this
press release, and we undertake no obligation to update or revise
any of the statements. We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release.
Contacts:
Scott YoungVice President, Corporate Communications &
Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Julie DownsAssociate Director, Corporate Communications &
Investor Relations Flexion Therapeutics, Inc.T:
781-305-7137jdowns@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Sep 2023 to Sep 2024